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INTRODUCTION
PERIODONTITIS, ONE OF THE most common oral inflam-matory infectious diseases and the leading cause of
tooth loss, is characterized by the destruction of tooth-sup-
porting tissues.1 Growth factors are natural biological mol-
ecules that mediate and regulate key cellular events dur-
ing tissue repair, including cell proliferation, chemotaxis,
differentiation, and matrix synthesis by binding to specific
cell-surface receptors.2–4 Platelet-derived growth factor
(PDGF), vascular endothelial growth factor (VEGF), and
pyridinoline cross-linked carboxyterminal telopeptide of
Type I collagen (ICTP) are mediators involved in mito-
genesis, angiogenesis, and bone turnover. These media-
tors are essential for wound regeneration of periodontal
tissues. Growth factors such as PDGF can stimulate cells
involved in periodontal regeneration and enhance peri-
odontal wound healing and regeneration.5,6 Some of these
inducible growth factors such as PDGF and VEGF can
work coordinately to stimulate osteogenesis and vascu-
logenesis.7–9 However, little is known regarding the re-
lease of these molecules into local periodontal wound
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ABSTRACT
Growth factors such as platelet-derived growth factor (PDGF) exert potent effects on wound heal-
ing including the regeneration of tooth-supporting structures. This investigation examined the ef-
fect of the local delivery of PDGF-BB when combined with reconstructive periodontal surgery on
local wound fluid (WF) levels of PDGF-AB, vascular endothelial growth factor (VEGF), and bone
collagen telopeptide (ICTP) in humans with advanced periodontitis. Sixteen patients exhibiting lo-
calized periodontal osseous defects were randomized to one of three groups (-TCP carrier alone,
-TCP  0.3 mg/mL of recombinant human PDGF-BB [rhPDGF-BB], or -TCP  1.0 mg/mL of
rhPDGF-BB) and monitored for 6 months. WF was harvested and analyzed for PDGF-AB, VEGF,
and ICTP WF levels. Teeth contralateral to the target lesions served as controls. Increased levels of
VEGF in the WF was observed for all surgical treatment groups with the 1.0 mg/mL rhPDGF-BB
group showing the most pronounced difference at 3 weeks in the AUC analysis versus control (p 
0.0001). PDGF-AB WF levels were increased for the carrier alone group compared to both rhPDGF-
BB groups. Low-dose rhPDGF-BB application elicited increases in ICTP at days 3–5 in the wound
healing process, suggesting a promotion of bone turnover at early stages of the repair process (p 
0.02). These results demonstrate contrasting inducible expression patterns of PDGF-AB, VEGF, and
ICTP during periodontal wound healing in humans.
1Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, Michigan.
2BioMimetic Therapeutics, Inc., Franklin, Tennessee.
3Department of Biomedical Engineering, College of Engineering, University of Michigan, Ann Arbor, Michigan.
4Michigan Center for Oral Health Research, University of Michigan Clinical Research Center, Ann Arbor, Michigan.
fluid (WF) or gingival crevicular fluid (GCF) during pe-
riodontal wound repair.
PDGF has shown strong effects in promoting bone and
soft tissue healing.5,6,10 The effect of exogenous PDGF-
BB on bone healing was tested in a pilot study using a
unilateral tibial osteotomy model in rabbits. PDGF-
treated tibiae displayed a more florid and advanced state
of osteogenic differentiation, both endosteally and pe-
riosteally, than the control defects. Data suggest that ex-
ogenous PDGF has a stimulatory effect on fracture heal-
ing, and systemic administration of PDGF increases bone
density and strength throughout the skeleton.11,12
Studies have clearly demonstrated the mechanism of
action of PDGF, showing the presence of cell-surface re-
ceptors for PDGF on periodontal ligament and alveolar
bone cells, and signal proliferative and chemotactic re-
sponses by these cells.13,14 Studies indicate that gingival
epithelium may be a source of PDGF A and B chains and
that the A chain may have a more prominent role to play
during early stages of healing.15,16 Additionally, recom-
binant human PDGF-BB (rhPDGF-BB) has been shown
to promote the regeneration of periodontal tissue includ-
ing bone, cementum, and periodontal ligament in nu-
merous animal and human studies.5,13,17–21 rhPDGF-BB
is approved by the FDA under the trade name Regranex®
for the treatment (improved healing) of chronic neuro-
pathic, diabetic cutaneous ulcers.
Gingival crevicular fluid (GCF) is an exudate that can
be harvested from the gingival crevice surrounding the
tooth, one that contains many biochemical factors in-
cluding growth factors.22–24 It is a complex mixture of
substances derived from serum, leukocytes, structural
cells of the periodontium, and oral bacteria.25 In health,
GCF represents a transudate of gingival tissue interstitial
fluid; however, as gingivitis and periodontitis develop,
GCF becomes true inflammatory exudate.26
The aim of this trial is to better understand the mecha-
nisms of wound healing by evaluating pyridinoline cross-
linked carboxyterminal telopeptide of Type I collagen
(ICTP), vascular endothelial growth factor (VEGF), and
platelet-derived growth factor (PDGF) measured from
periodontal wound fluid (WF) during wound healing af-
ter reconstructive therapy after local PDGF-BB applica-
tion. The results of this study demonstrate the sequential
release and inducible expression patterns of these wound
healing mediators during periodontal tissue repair.
MATERIALS AND METHODS
This investigation evaluated 16 human subjects from
the University of Michigan School of Dentistry. Patients
involved in the study possessed localized severe peri-
odontal disease requiring periodontal regeneration sur-
gery. The patients in this study were a subset of research
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subjects participating in a pivotal clinical trial designed to
evaluate the safety and effectiveness of rhPDGF-BB to
promote soft and hard tissue engineering of the periodon-
tium.27 The subjects provided GCF (or periodontal WF)
after the delivery of grafts containing beta-tricalcium phos-
phate (-TCP) (VitOss®, Orthovita, Malvern, PA) with or
without rhPDGF-BB (combined product: GEM21S™,
BioMimetic Therapeutics, Inc., Franklin, TN) to severe pe-
riodontal osseous defects. Informed consent was obtained
at the initial visit prior to administration of any research-
related treatment or procedure. The study protocol con-
formed to the ethical guidelines of the 1975 Declaration
of Helsinki as reflected in obtainment of approval by the
University of Michigan’s human subjects research review
committee.
Inclusion/exclusion criteria
Subjects were entered into the study if they were be-
tween 25 and 75 years of age and had no evidence of lo-
calized aggressive periodontitis. Patients qualified for the
study if one tooth exhibited a soft tissue probing pocket
depth measuring 7 mm or greater, and after surgical de-
bridement, a 4 mm or greater vertical bone defect was
present with at least one bony wall. Patients were ex-
cluded if they were unable to maintain the health of the
site or were pregnant. The following were also exclu-
sionary factors at baseline: diagnosis of oral cancer or
human immunodeficiency virus within 6 months, previ-
ous periodontal surgery within 1 year on the study tooth,
tooth mobility greater than grade II, radiographic signs
of untreated acute infection at the surgical site, or recent
history of smoking more than 20 cigarettes/day.
Randomization and surgical treatment
Subjects were randomized in equal proportions into
one of three treatment groups: -TCP carrier alone (ac-
tive control), -TCP  0.3 mg/mL of rhPDGF-BB, or 
-TCP  1.0 mg/mL of rhPDGF-BB. Sites contralateral
to the target lesions served as nonsurgical controls.
Before surgical treatment, each subject received nonsur-
gical therapy consisting of scaling and root planing to con-
trol the disease process and prepare the defect site for 
surgical treatment. Surgical treatment consisted of full-
thickness mucoperiosteal flaps to allow adequate visual-
ization of the osseous lesion. After debridement of the test
site, the bone defect was measured and if found to be 4
mm vertically, final subject eligibility was confirmed and
the root surfaces were decontaminated with a tetracycline
paste. The test sites were then treated with -TCP  buffer
containing rhPDGF-BB, and the flaps were secured with
interdental sutures to achieve primary closure. Subjects
were instructed to utilize an oral antimicrobial rinse of
chlorhexidine (0.12%) twice daily for 6 weeks. Amoxicillin
500 mg three times daily for a minimum of 10 days (or an-
other appropriate antibiotic regimen) was prescribed.
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Wound healing score
During the first four follow-up visits, the healing con-
dition of the soft tissues at the surgical site was exam-
ined by visual inspection. A secondary endpoint, wound
healing (WH) score, was recorded to reflect the extent of
healing (WH) at the surgical site.28 Wound Healing
Scale: 0  Absence of inflammation, normal healthy ap-
pearance to the tissues superficial to the graft, closed sur-
gical wound; 1  Mild inflammation; slight marginal
change in color (e.g., redness), little change in texture of
any portion of the marginal or papillary gingival unit su-
perficial to the graft, closed surgical wound; 2  Mild
inflammation; criteria as above but involving the entire
marginal or papillary unit, closed surgical wound; 3 
Moderate inflammation; glazing, redness, edema, and/or
hypertrophy of the marginal or papillary unit, bleeding
upon gentle palpation, gingival wound open 2 mm; 
and 4  Severe inflammation; marked redness, edema,
and/or hypertrophy of the marginal or papillary gingival
unit, spontaneous bleeding, congestion, gingival wound
open 2 mm.
Periodontal wound fluid collection
Four teeth were used as WF collection sites in each
subject. Three contralateral teeth served as the nonsurgi-
cal control sites, and one tooth received the surgery 
device: -TCP with buffer alone (active control), -TCP,
with buffer containing 0.3 mg/mL of rhPDGF-BB, or -
TCP, with buffer containing 1.0 mg/mL of rhPDGF-BB.
The WF samples were taken from the mesiobuccal as-
pect of each tooth except for the defect site where sam-
ples were directly taken. The area around each sample
site was air-dried and the supragingival plaque biofilm
was removed. A sterile methylcellulose strip (Pro Flow,
Inc., Amityville, NY) was gently inserted into the gingi-
val sulcus or periodontal pocket until slight resistance
was felt. The fluid sample was then collected for 10 sec-
onds and the strips were then immediately placed into
Eppendorf tubes. The samples were subsequently kept on
ice for transport to the laboratory, where they were stored
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at 80°C until needed for analysis of ICTP, VEGF, and
PDGF-AB. The collection of WF occurred at nine dif-
ferent time points (Fig. 1): Baseline; between Days 3–5,
6–9, 12–15, 19–24; and at weeks 6, 12, 18, and 24 after
reconstructive surgery.
Biomarker analysis
ICTP evaluation. Frozen samples were thawed at room
temperature and the proteins were then eluted through cen-
trifugation 5 in 12  75 mL polypropylene tubes at 3000
RPM for 5 min with 20 L phosphate-buffered saline (pH
7.4) containing 15 nM aprotinin, 1 mM polymethyl sul-
fonyl fluoride (PMSF), and 0.1% of human serum albu-
min as previously described.29 GCF/WF ICTP levels were
quantified using radioimmunoassay (RIA) (DiaSorin Inc.,
Stillwater, MN) as previously described.30 ICTP was de-
termined as total amount/10-second time collection
(pg/site).
VEGF evaluation. Frozen samples were thawed at
room temperature and then the proteins were eluted us-
ing a rocker for 2 h at 4°C in 200 L of buffer as pre-
viously described.31 The buffer contained antipain, apro-
tinin, leupeptin, n-ethyl malemide, and zwittergent.
GCF/WF VEGF levels were quantified using enzyme-
linked immunosorbent assay (ELISA) according to the
manufacture’s protocol (R&D Systems Inc., Minneapo-
lis, MN). VEGF was determined as total amount/10-sec-
ond collection (pg/site).
PDGF-AB evaluation. Frozen samples were thawed at
room temperature and then the proteins were eluted us-
ing a rocker for 2 h at 4°C in diluent from the ELISA kit
(R&D Systems, Inc.). GCF/WF PDGF-AB levels were
quantified using ELISA according to the manufacturer’s
protocol. PDGF-AB was determined as total amount/10-
second collection (pg/site). The assay is specific for
PDGF-AB that would presumably be released endoge-
nously, not detecting the applied rhPDGF-BB. No sig-
nificant cross-reaction between the isoforms occurs, ac-
cording to the manufacturer’s instructions.
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FIG. 1. Study timeline. GCF, gingival crevicular fluid; WF, periodontal wound fluid; WH, wound healing score.
STATISTICAL ANALYSIS
The standard statistics and statistical modeling proce-
dures using analysis of variance (ANOVA) Fishers pro-
tected least significant difference (PLSD) post hoc test at
the 5% level were used to examine the differences in me-
diator values between the different treatment groups. A
longitudinal analysis was used to take into account non-
independence. Each model was run with the mediator
level area under the curve (AUC) analysis as the depen-
dent variable, and each of the surgery groups as the in-
dependent variables. AUC analysis was performed for
two different time points: baseline–3 weeks and base-
line–24 weeks. The evaluation over the first 3 weeks is
the time frame in which initial healing is complete and
complete closure of the wound occurs in the sites that re-
ceived periodontal grafting surgery. The baseline–24-
week AUC analysis accounts for the observation period
that includes bone repair and maturation. The following






Statistical analysis using AUC was performed using
ANOVA Fishers post hoc test at the 5% level.
RESULTS
The mean age for all patients was 49.8 years with a
range of 26–68 years. Half of the patients involved in the
study were male (8) and half were female (8). A total of
6 patients in the study were considered smokers and 10
were nonsmokers. The -TCP carrier alone group con-
tained 2 current smokers, the 0.3 mg/mL of rhPDGF-BB
group had 1 current smoker, and the 1.0 mg/mL of rh-
PDGF-BB group had 3 current smokers. For the test
groups, baseline mean probing depth (PD) was 8.1 mm,
baseline clinical attachment level (CAL) was 8.8 mm,
and the mean bone defect depth was 5.25 mm. The non-
surgical control mean PD was 3.3 mm and the mean CAL
was 3.5 mm. No statistical differences were found be-
tween surgical treatment groups and pretreatment mea-
surements at baseline.
Figure 1 illustrates the timeline for the WF collection.
The collection of WF occurred at nine different time
points: Baseline; between Days 3–5, 6–9, 12–15, 19–24;
and at Week 6, 12, 18, and 24 after reconstructive sur-
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gery. Clinical and radiographic examinations occurred at
the baseline time point presurgically and at Week 12. A
wound healing score was recorded during the first four
postsurgical visits. As expected, the wound healing
scores decreased linearly over the first four time points
(data not shown). With this relatively small sample size,
no differences were found between groups regarding
wound healing scores.
Figure 2A is a graph of VEGF (pg/site) over time for
all groups. The nonsurgical control shows little change
in the amount of VEGF released in the PWF throughout
the study. For the test groups (0, 0.3, and 1.0 mg/mL rh-
PDGF-BB) there is an immediate increase in the amount
of VEGF released over the first 12–15 days compared to
the nonsurgical control group (p  0.05), but not for car-
rier alone (NS). The increase of VEGF release peaked at
day 12–15 and gradually decreased to baseline values
over the remainder of the study. Among the treatment
groups, the 1.0 mg/mL PDGF-BB group had the great-
est amount of VEGF released with a maximum average
of 38.4 pg/site at days 12–15, although this difference
was not statistically significant. The 0.3 mg/mL PDGF-
BB group and -TCP carrier alone group had similar lev-
els of VEGF release throughout the study. Their levels
also peaked at days 12–15, although with slightly lower,
nonsignificant values than the 1.0 mg/mL PDGF-BB
group. Figure 2B is an AUC analysis for VEGF over the
first 3 weeks. The AUC analysis estimates the amount of
the mediator released over a period of time. Statistically
significant differences were observed between the non-
surgical control and all treatment groups. Figure 2C is an
AUC analysis of VEGF for all groups over 24 weeks.
Again, statistical differences were observed between the
nonsurgical control and all treatment groups (p  0.05).
Over the 24-week time frame, the AUC for the different
treatment groups leveled out to similar AUC values.
Figure 3A shows endogenous PDGF-AB release
(pg/site) over time for all groups. The amount of PDGF-
AB released remained low for all groups at all time points.
The -TCP carrier alone group showed an increase of
PDGF-AB production at Days 3–5 and 6–9. No statistical
differences were observed between treatment groups or be-
tween the 0.3 mg/mL PDGF-BB group and the 1.0 mg/mL
PDGF-BB group versus the nonsurgical control. Figure 3B
is an AUC analysis for PDGF-AB release over the first 3
weeks. A statistically significant difference was observed
between the nonsurgical control and the -TCP carrier
alone group (p  0.05). No statistical differences were ob-
served between treatment groups or between the 0.3
mg/mL PDGF-BB group and the 1.0 mg/mL PDGF-BB
group versus the nonsurgical control over the first 3 weeks.
Figure 3C is an AUC analysis of PDGF-AB for all groups
over 24 weeks. The AUC for the 0.3 mg/mL PDGF-BB
group and the 1.0 mg/mL PDGF-BB group were similar
to that of the nonsurgical control.
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Figure 4A is a graph of ICTP release (pg/site) over
time for all groups. The nonsurgical control shows little
change in the amount of ICTP released in the WF
throughout the study. The 0.3 mg/mL PDGF-BB group
and the 1.0 mg/mL PDGF-BB group had an increase in
the amount of ICTP released at the Day 3–5 time point,
with the average amount of ICTP released from the 0.3
mg/mL PDGF-BB group (335.6 pg/site) being more pro-
nounced than the 1.0 mg/mL PDGF-BB group (161
pg/site), although not statistically significant. Figure 4B
is an AUC analysis of ICTP over the first 3 weeks. The
AUC for the surgical treatment groups was higher than
the nonsurgical control, although not statistically signif-
icant. The 0.3 mg/mL PDGF-BB group had a higher AUC
compared to the other treatment groups, but it was not
statistically significant. Figure 4C is an AUC analysis of
ICTP for all groups for 24 weeks. The AUC was similar
for the 0.3 mg/mL PDGF-BB group and the 1.0 mg/mL
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PDGF-BB group, and was similar for the -TCP carrier
alone group and the nonsurgical control.
DISCUSSION
PDGF is a mitogen and chemoattractant for cells of
mesenchymal origin including osteoblasts, and gingival
and periodontal fibroblasts.32 The PDGF molecule con-
sists of two disulfide-polypeptide chains that are encoded
by two genes, pdgf-a and pdgf-b. Cells such as degranu-
lating platelets, osteoblasts, smooth muscle fibroblasts,
endothelial cells, macrophages, and keratinocytes pro-
duce PDGF.33 PDGF is an important stimulator of an-
giogenesis and wound healing in tissues such as skin,
bone, and periodontium.33 It has been shown that in der-
mal wounds, the epidermis is a primary source of
PDGF.34 Gingival epithelium may be a source of both
1445
FIG. 2. PDGF tissue engineering of periodontal defects pro-
motes local release of vascular endothelial growth factor. (A)
Graph of VEGF (pg/site) versus timepoint for all groups: -
TCP carrier alone, 0.3mg/mL PDGF, 1.0 mg/mL PDGF, and
the nonsurgical control. Statistically significant differences
were found between all treatment groups and the nonsurgical
control (p  0.05) except for Days 6–9 and Week 12. A sta-
tistically significant difference was also found between the 0.3
mg/mL PDGF group and the 1.0 mg/mL PDGF group at Days
3–5 (p  0.05). (B) Area under the curve (AUC) analysis for
VEGF up to 3 weeks. The most pronounced statistically sig-
nificant difference was found between the nonsurgical control
and the 1.0 mg/mL PDGF group (p  0.0001). Statistically sig-
nificant differences were also observed between the nonsurgi-
cal control and the -TCP carrier alone group (p  0.0005) and
the 0.3 mg/mL PDGF group (p  0.005). The AUC for VEGF
was highest for the 1.0 mg/mL PDGF group compared to the
other surgical treatment groups, although there were no statis-
tically significant differences between these treatment groups.
(C) Area under the curve (AUC) analysis for VEGF of all time-
points. Statistically differences were observed between the non-
surgical control and all treatment groups (p  0.05). No statis-
tically significant differences were found between treatment
groups. Statistical analysis was performed using ANOVA
Fisher test at the 5% level. A total of 15 patients were analyzed
for VEGF. Bars indicate standard error measurements (SEM).
PDGF protein and PDGF receptors, because both are in-
duced at the wound site after injury and possibly regu-
late wound healing events.15
VEGF possesses strong mitogenic, angiogenic, and vas-
cular permeability-enhancing activities. Angiogenesis is a
major component of wound healing that begins by dis-
rupting the continuity of pre-existing blood vessels. En-
dothelial cells migrate and proliferate from the area of the
degraded basement membrane to form new capillaries.
VEGF promotes angiogenesis by stimulating migration of
endothelial cells through the extracellular matrix via a cas-
cade of ligand/receptor interactions.35 In addition to its
own receptor interactions, VEGF upregulates the expres-
sion of other surface molecules including intercellular ad-
hesion molecule (ICAM-1) and vascular cell adhesion
molecule (VCAM-1), which are molecules involved in
cell–cell signaling.36 VEGF has also been recently assayed
from the GCF derived from healthy and diseased peri-
odontal patients.37 Higher levels of VEGF were found in
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chronically diseased sites than in healthy sites. In addition
to its role in the regulation of angiogenesis, VEGF has
been recently suggested to play an important role in the
regulation of bone remodeling by attracting endothelial
cells and osteoclasts, and stimulating osteoblast differen-
tiation.38–41 The role of VEGF related to neovasculariza-
tion in periodontal wounds has not been studied to date.
Yao et al.42 compared reepithelialization, contraction
rates, and growth factor profiles in full-thickness porcine
wounds. The results showed that endogenous VEGF con-
centrations peaked on day 4, reaching levels of 420 to
482 pg/mL. A comparison of PDGF-BB concentrations
showed similar patterns (peaks of 77–91 pg/mL on days
2 and 3). On day 11, wound contraction in 2-month-old
pigs was about 10% faster than in 24-month-old pigs (p 
0.05).42 Early healing events in periodontal and epider-
mal wounds can be compared and contrasted to identify
those stages that are critical to the outcome of healing af-
ter periodontal regeneration.43,44
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FIG. 3. Effect of PDGF-BB-mediated tissue engineering of
periodontal defects on local PDGF-AB release. (A) Graph of
PDGF-AB release (pg/site) versus time point for all groups: -
TCP carrier alone, 0.3 mg/mL PDGF-BB, 1.0 mg/mL PDGF-
BB, and the nonsurgical control. A statistically significant dif-
ference was observed between the -TCP carrier alone group
and the nonsurgical control at Days 3–5 (p  0.04). The 0.3
mg/mL PDGF-BB group and the 1.0 mg/mL PDGF-BB group
had similar levels of PDGF-AB released throughout the study.
(B) Area under the curve (AUC) analysis for PDGF-AB up to
3 weeks. A statistically significant difference is observed only
between the nonsurgical control and the -TCP carrier alone
group (p  0.05). (C) Area under the curve (AUC) analysis for
PDGF-AB release at all time points. Statistically significant dif-
ferences were not observed when evaluating over 24 weeks for
any groups. Statistical analysis was performed using ANOVA
Fisher test at the 5% level. A total of 14 patients were analyzed
for PDGF-AB (endogenous). Bars indicate standard error mea-
surements (SEM).
Pyridinoline cross-linked carboxyterminal telopeptide
of type I collagen (ICTP) is a member of collagen degrada-
tive molecules that include pyridinoline, deoxypyridino-
line, N-telopeptides, and C-telopeptides.23 Pyridinoline
(Pyr) and deoxypyridinoline (Dpy) are nonreducible
crosslinks present in the mature form of collagen.45 Pyr
and Dpy form extracellularly and stabilize collagen mole-
cules during maturation of the matrix of bone and carti-
lage.46 Before osteoclastic bone resorption and collagen
matrix degradation, Pyr, Dpy, and amino-, and the car-
boxy-terminal crosslinked telopeptides of type I collagen
are released into the tissue fluid. They are considered spe-
cific molecules found after the earliest bone resorption, and
these molecules are not reused for new collagen synthe-
sis.23 For this reason, pyridinoline cross-links have
emerged as promising biomarkers of bone resorption and
turnover. Recent studies have used ICTP levels to evalu-
ate the response to periodontal therapy, and have demon-
strated significant correlations between local ICTP levels
and clinical measures of periodontal disease.46,47
The growth factors evaluated in this study are known
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to mediate and regulate cellular events during wound
healing such as cell proliferation, chemotaxis, differenti-
ation, and matrix synthesis.2–4,10 Specifically, this study
evaluated the release of the growth factors PDGF-AB and
VEGF as well as ICTP in the periodontal WF after a 
periodontal bone grafting procedure.
This study reveals contrasting inducible expression pat-
terns of PDGF-AB, VEGF, and ICTP during periodontal
wound healing in humans. Specifically, the levels of
VEGF show increased levels in the surgical test sites for
all test groups peaking at Days 12–15. The high-dose
PDGF-BB (1.0 mg/mL) group promoted the highest lev-
els of VEGF release over the 24-week observation period,
although not significantly different from the other test
groups. The use of an AUC analysis allows for a total es-
timate of mediator release over the course of the study
rather than at specific time points. Using an AUC analy-
sis, statistically significant differences were found for the
total amount of VEGF released between the treatment ver-
sus nonsurgical groups over the first 3 weeks and at the
24-week time point. Of interest, several studies have dem-
1447
FIG. 4. Effect of PDGF-mediated tissue engineering of peri-
odontal defects on local pyridinoline cross-linked carboxyter-
minal telopeptide of type I collagen (ICTP) release. (A) Graph
of ICTP (pg/site) versus time point for all groups: -TCP car-
rier alone, 0.3 mg/mL PDGF-BB, 1.0 mg/mL PDGF-BB, and
the nonsurgical control. Statistically significant differences were
observed between the 0.3 mg/mL PDGF-BB group and the non-
surgical control (p  0.003) and between the 0.3 mg/mL PDGF-
BB group and the -TCP carrier alone group (p  0.02) at the
Day 3–5 timepoint. At 6 weeks, statistically significant differ-
ences were observed for the following groups: -TCP carrier
alone versus the 0.3 mg/mL PDGF-BB (p  0.03), -TCP car-
rier alone versus the 1.0 mg/mL PDGF-BB (p  0.01), and the
1.0 mg/mL PDGF-BB versus nonsurgical control (p  0.03). (B)
Area under the curve (AUC) analysis for ICTP up to 3 weeks.
No statistically significant differences were found between treat-
ment groups. (C) AUC analysis for ICTP of all timepoints. No
statistically significant differences were observed between any
groups. Statistical analysis was performed using ANOVA Fisher
test at the 5% level. A total of 14 patients were analyzed for
ICTP. Bars indicate standard error measurements (SEM).
onstrated the coordinated effects of PDGF and VEGF on
the promotion of vasculogenesis. PDGF promotes blood
vessel smooth muscle pericyte formation, whereas VEGF
promotes endothelial cell proliferation.8,9 Together, the
two factors work to potently promote angiogenesis, a key
determinant in stimulating bone regeneration. The result
found here that periodontal injury induces VEGF release
is suggestive that it may have promoted a greater clinical
response in patients receiving rhPDGF-BB as shown in
the pivotal clinical trial results.27
The level of PDGF-AB released from the WF between
groups showed a statistically significant difference only
at the Day 3–5 time point for -TCP carrier alone ver-
sus nonsurgical control (p  0.04). However, there was
an increase in the amount of PDGF-AB released at Days
3–5 and 6–9 for the -TCP carrier alone group. The AUC
analysis for PDGF-AB release into PWF only showed a
statistically significant difference over the first 3 weeks
for the -TCP carrier alone group versus the nonsurgical
group (p  0.05). No statistically significant differences
were observed over the 24-week time frame. These data
are suggestive that exogenous PDGF-BB does little to af-
fect increases and tends to decrease endogenous release
of PDGF-AB. This result could be explained by a feed-
back inhibition of PDGF expression due to bolus deliv-
ery of exogenous PDGF-BB. An expanded study would
be necessary to better understand this potential mecha-
nism.
The amount of ICTP released from the WF showed an
apparent increase in the amount of ICTP released at Days
3–5 for the 0.3 mg/mL PDGF group that was statistically
significant versus the -TCP carrier alone group (p 
0.02) and nonsurgical control groups (p  0.003). The
AUC analysis for ICTP released into the WF did not show
any statistically significant differences at the 3-week or
24-week time points. A recent report describes longer-
term release of ICTP from periodontal wounds treated by
PDGF.48
Final clinical outcomes from the multicenter parent
study show a mean increase in linear bone growth of 2.6
mm for the 0.3 mg/mL PDGF-BB group, 1.5 mm for the
1.0 mg/mL PDGF group, and 0.9 mm for the -TCP car-
rier alone group. Mean percent bone fill was reported to
be 57% for the 0.3 mg/mL PDGF-BB group, 34% for the
1.0 mg/mL PDGF-BB group, and 18% for the -TCP
carrier alone group.27 Comparisons of both concentra-
tions of rhPDGF-BB demonstrated statistically signifi-
cant improvements compared to the -TCP carrier alone
group.
In conclusion, data from this study show that when
PDGF-BB is delivered to promote periodontal tissue en-
gineering of tooth-supporting osseous defects, there is a
clinical and biological effect on growth factors released
from the wound. VEGF is induced during wound repair,
whereas exogenous PDGF-BB may reduce the release of
COOKE ET AL.
endogenous PDGF-AB from the wound site after several
days of healing. It also appears that there may be a
marked increase in bone turnover during the first few
days of wound healing when PDGF-BB is added to the
osteoconductive scaffold, because the amount of ICTP
release from the wound was increased for the 0.3 mg/mL
PDGF-BB group. Future studies with expanded patient
populations will be needed to better understand the ef-
fects of rhPDGF-BB on periodontal wound healing.
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